Cyprodime
 | |
 | |
| Clinical data | |
|---|---|
| Other names | Cyprodime |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H29NO3 |
| Molar mass | 355.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Cyprodime is an opioid antagonist from the morphinan family of drugs.
Cyprodime is a selective opioid antagonist which blocks the μ-opioid receptor,[1] but without affecting the δ-opioid or κ-opioid receptors. This makes it useful for scientific research as it allows the μ-opioid receptor to be selectively deactivated so that the actions of the δ and κ receptors can be studied separately, in contrast to better known opioid antagonists such as naloxone which block all three opioid receptor subtypes.[2]
See also
[edit]- Tianeptine, an atypical, selective MOR full-agonist licensed for major depression since 1989.
- Samidorphan, an opioid antagonist preferring the MOR, which is under development for major depression.
References
[edit]- ↑ Schmidhammer H, Burkard WP, Eggstein-Aeppli L, Smith CF (February 1989). "Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective mu opioid receptor antagonist". Journal of Medicinal Chemistry. 32 (2): 418–21. doi:10.1021/jm00122a021. PMID 2536439.
- ↑ Márki A, Monory K, Otvös F, Tóth G, Krassnig R, Schmidhammer H, et al. (October 1999). "Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays". European Journal of Pharmacology. 383 (2): 209–14. doi:10.1016/s0014-2999(99)00610-x. PMID 10585536.
 | This analgesic-related article is a stub. You can help Wikipedia by adding missing information. |